CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Rhea-AI Summary

CVRx (NASDAQ: CVRX) announced enrollment of the first patient in the BENEFIT-HF trial on May 4, 2026. The prospective, randomized, controlled study plans to enroll 2,500 patients at ~150 U.S. and Germany centers and is supported by CMS Category B IDE.

The trial will evaluate all-cause mortality and heart failure decompensation events through 2032 and, if successful, could expand the Barostim indicated population by about threefold.

Positive

• Planned enrollment of 2,500 patients
• Supported by CMS Category B IDE coverage
• Multicenter design across ~150 centers in US and Germany

Negative

• Trial timeline extends through 2032, delaying potential outcomes
• Primary endpoints require substantial event accrual to assess mortality
• Expansion of indicated population depends on a successful trial result

News Market Reaction – CVRX

-3.78%

1 alert

-3.78% Session close to close

$195.99M Market Cap

0.1x Rel. Volume

In the May 5 session, CVRX declined 3.78%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement marked the first patient enrollment in BENEFIT-HF, a large randomized heart failur...

Analysis

This announcement marked the first patient enrollment in BENEFIT-HF, a large randomized heart failure trial of Barostim targeting 2,500 patients at about 150 centers, with follow-up expected through 2032. It builds on earlier updates about trial activation and reimbursement progress. Historically, CVRx has seen mixed share reactions to positive fundamentals, including a sharp move after Q4/FY 2025 results. Investors may focus on trial execution, future data, capital needs under the $150M shelf, and reimbursement trends as the study progresses.

Key Figures

Planned enrollment: 2,500 patients Trial centers: Approximately 150 centers Trial duration: Through 2032

3 metrics

Planned enrollment 2,500 patients BENEFIT-HF heart failure device trial size

Trial centers Approximately 150 centers BENEFIT-HF sites in U.S. and Germany

Trial duration Through 2032 Expected BENEFIT-HF trial timeline

Historical Context

5 past events · Latest: Apr 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	Earnings call schedule	Neutral	-2.2%	Announced date and time for Q1 2026 earnings release and call.
Apr 20	Board nomination	Positive	+5.0%	Nominated experienced structural heart executive Michael Dale to board.
Apr 13	Preliminary earnings	Positive	+9.2%	Reported Q1 2026 revenue growth and strong gross margin with solid cash.
Mar 02	Clinical data presentations	Positive	+0.7%	Highlighted Barostim outcomes and initiation plans for BENEFIT-HF at THT.
Feb 12	Q4/FY 2025 earnings	Positive	-13.0%	Reported revenue growth, higher gross margin, more centers, and new term loan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and financial updates have often led to gains, though the stock sold off on the strong Q4/FY 2025 report, indicating occasional divergence on fundamentally positive news.

Recent Company History

Over the last few months, CVRx has combined financial progress with expanding clinical evidence for Barostim. Preliminary Q1 2026 results showed revenue growth around 20% with gross margin near 87%, and the company highlighted growing reimbursement support and more implanting centers. Prior news also detailed the initiation of BENEFIT-HF and scientific presentations at THT 2026. Governance developments included a new director nominee with structural heart experience and a scheduled Q1 2026 earnings call. Today’s first-patient enrollment update builds directly on earlier announcements about activating BENEFIT-HF sites and planned enrollment in 2026.

Key Terms

neuromodulation, heart failure decompensation, CMS Category B IDE coverage, guideline-directed medical therapy, +2 more

6 terms

neuromodulation medical

"a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

heart failure decompensation medical

"designed to evaluate all-cause mortality and heart failure decompensation events"

Heart failure decompensation is when a chronic weak heart suddenly cannot keep up with the body's needs, causing symptoms like shortness of breath, fluid buildup, and fatigue; think of a household pump that starts failing and lets water overflow. For investors, these episodes drive demand for hospital care, drugs, monitoring devices and procedures, influence clinical trial results and regulatory decisions, and can significantly affect healthcare costs and company revenue streams.

CMS Category B IDE coverage regulatory

"The prospective, randomized, controlled, multicenter trial is supported by CMS Category B IDE coverage"

CMS Category B IDE coverage is a Medicare policy that determines when Medicare will pay for routine care and certain costs tied to clinical trials of investigational medical devices operating under an Investigational Device Exemption (IDE). For investors, this matters because CMS coverage decisions influence patient access and trial enrollment, which can speed or slow a device maker’s path to market and future revenue — like whether a bridge is open for traffic, affecting how quickly goods can move.

guideline-directed medical therapy medical

"patients who remain symptomatic despite optimized guideline-directed medical therapy"

Guideline-directed medical therapy is the set of treatments doctors are recommended to use for a specific disease based on expert consensus and clinical evidence, like following a trusted recipe for best results. It matters to investors because whether a new drug or device becomes part of that standard affects how widely it will be adopted, how insurers pay for it, and how companies compare in clinical studies—factors that influence sales, regulatory success, and long-term value.

all-cause mortality medical

"designed to evaluate all-cause mortality and heart failure decompensation events"

All-cause mortality is the total number of deaths from any cause within a defined group over a specific time period. For investors, it is a broad safety and outcome measure used in clinical trials and public-health studies—like counting everyone who leaves a club for any reason—because higher or lower all-cause mortality can influence regulatory decisions, product reputation, long-term liability and market value.

randomized, controlled, multicenter trial medical

"The prospective, randomized, controlled, multicenter trial is supported by CMS Category B IDE coverage"

A randomized, controlled, multicenter trial is a clinical study in which participants are randomly assigned to receive one of the treatments or a control (such as a placebo) and the study is conducted at multiple independent sites. For investors, this design provides stronger, more reliable evidence about a treatment’s safety and effectiveness—like testing a product across many stores—reducing the chance that results are due to chance or a single location and informing regulatory approval and market potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the landmark BENEFIT-HF trial at North Central Heart - a division of the Avera Heart Hospital, in Sioux Falls, S.D. by Dr. Orvar Jonsson.

BENEFIT-HF is expected to be one of the largest therapeutic cardiac device trials ever performed in heart failure, enrolling 2,500 patients at approximately 150 centers in the United States and Germany. The prospective, randomized, controlled, multicenter trial is supported by CMS Category B IDE coverage and designed to evaluate all-cause mortality and heart failure decompensation events in a significantly expanded heart failure population.

“We are honored to enroll the first patient in the BENEFIT-HF trial,” said Dr. Orvar Jonsson, North Central Heart - a division of the Avera Heart Hospital. “This study will evaluate Barostim therapy in a broader population of patients who remain symptomatic despite optimized guideline-directed medical therapy, generating important data that will further define Barostim’s position in the heart failure continuum.”

“Achievement of this early milestone reflects tremendous excitement in the healthcare community regarding this landmark trial, and strong execution by the CVRx team in partnership with BENEFIT-HF investigators,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “We are proud to collaborate with leading physicians in development of such meaningful clinical evidence, and excited to further characterize the patient benefits of Barostim therapy that we believe will drive long-term adoption.”

The BENEFIT-HF trial is expected to continue through 2032. If successful, the Trial could expand the indicated patient population for Barostim by approximately three times, significantly broadening access to the therapy.

About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected timing, enrollment, scope, and outcomes of the BENEFIT-HF clinical trial, potential expansion of the Barostim indication, and anticipated benefits of Barostim therapy. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our expectations regarding enrollment; the resulting impact on our addressable market; impacts on adoption and regulatory approvals resulting from additional long-term clinical data about our product, including those resulting from the BENEFIT-HF clinical trial; and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

FAQ

What is the BENEFIT-HF trial that CVRX (NASDAQ:CVRX) launched on May 4, 2026?

BENEFIT-HF is a randomized, controlled trial enrolling 2,500 patients to evaluate Barostim. According to the company, it will run at ~150 centers in the US and Germany and is supported by CMS Category B IDE.

What endpoints will the BENEFIT-HF trial (CVRX) measure and why do they matter?

The trial measures all-cause mortality and heart failure decompensation events as primary endpoints. According to the company, these endpoints aim to quantify survival and hospitalization-related outcomes for symptomatic heart failure patients.

How long will the BENEFIT-HF trial for CVRX run and when are results expected?

The BENEFIT-HF trial is expected to continue through 2032. According to the company, that timeline reflects the large enrollment target and the need to accrue sufficient clinical events for analysis.

How could a successful BENEFIT-HF trial affect Barostim's indicated patient population for CVRX?

If successful, the trial could expand the Barostim indicated population by approximately three times. According to the company, broader labeling could significantly increase eligible patients for the therapy.

Where was the first patient for CVRX's BENEFIT-HF enrolled and who performed the procedure?

The first patient was enrolled at North Central Heart, Avera Heart Hospital in Sioux Falls, S.D. According to the company, Dr. Orvar Jonsson performed the enrollment procedure.